Astria Therapeutics (ATXS) Competitors $7.50 -0.25 (-3.23%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATXS vs. GLPG, ARQT, INDV, AKRO, DYN, IMCR, EVO, TVTX, VIR, and GPCRShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Galapagos (GLPG), Arcutis Biotherapeutics (ARQT), Indivior (INDV), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Immunocore (IMCR), Evotec (EVO), Travere Therapeutics (TVTX), Vir Biotechnology (VIR), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Galapagos Arcutis Biotherapeutics Indivior Akero Therapeutics Dyne Therapeutics Immunocore Evotec Travere Therapeutics Vir Biotechnology Structure Therapeutics Galapagos (NASDAQ:GLPG) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk. Do insiders and institutionals have more ownership in GLPG or ATXS? 32.5% of Galapagos shares are owned by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Comparatively, 2.9% of Astria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate GLPG or ATXS? Galapagos presently has a consensus price target of $30.75, indicating a potential upside of 29.42%. Astria Therapeutics has a consensus price target of $25.60, indicating a potential upside of 241.33%. Given Astria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Astria Therapeutics is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galapagos 3 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.63Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has more volatility & risk, GLPG or ATXS? Galapagos has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Does the media refer more to GLPG or ATXS? In the previous week, Astria Therapeutics had 7 more articles in the media than Galapagos. MarketBeat recorded 11 mentions for Astria Therapeutics and 4 mentions for Galapagos. Galapagos' average media sentiment score of 0.47 beat Astria Therapeutics' score of 0.46 indicating that Galapagos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galapagos 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Astria Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in GLPG or ATXS? Astria Therapeutics received 100 more outperform votes than Galapagos when rated by MarketBeat users. Likewise, 72.94% of users gave Astria Therapeutics an outperform vote while only 64.01% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformGalapagosOutperform Votes46664.01% Underperform Votes26235.99% Astria TherapeuticsOutperform Votes56672.94% Underperform Votes21027.06% Which has higher valuation and earnings, GLPG or ATXS? Galapagos has higher revenue and earnings than Astria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalapagos$259.40M6.04$229.12MN/AN/AAstria TherapeuticsN/AN/A-$72.89M-$2.09-3.59 Is GLPG or ATXS more profitable? Galapagos' return on equity of 0.00% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GalapagosN/A N/A N/A Astria Therapeutics N/A -43.58%-29.36% SummaryAstria Therapeutics beats Galapagos on 9 of the 15 factors compared between the two stocks. Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$420.43M$6.37B$5.23B$8.96BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-3.599.4187.2917.29Price / SalesN/A310.261,255.8979.02Price / CashN/A61.4443.8235.97Price / Book2.256.055.324.79Net Income-$72.89M$154.90M$122.78M$225.07M7 Day Performance0.67%-1.72%-0.19%1.51%1 Month Performance-19.87%2.69%3.72%4.68%1 Year Performance5.49%2.78%27.31%20.92% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics1.4785 of 5 stars$7.50-3.2%$25.60+241.3%-0.8%$420.43MN/A-3.5930Short Interest ↑GLPGGalapagos1.6814 of 5 stars$24.24-5.5%$30.75+26.9%-38.6%$1.60B$260.09M0.001,123ARQTArcutis Biotherapeutics2.4311 of 5 stars$13.63-1.3%$16.60+21.8%+279.6%$1.60B$138.71M-7.61150Short Interest ↓Gap UpINDVIndivior2.1017 of 5 stars$11.51-2.9%$16.00+39.0%-24.8%$1.59B$1.18B-287.681,164Short Interest ↑News CoverageAKROAkero Therapeutics3.8446 of 5 stars$22.63-8.9%$46.83+107.0%+15.3%$1.58BN/A-6.0330Analyst ForecastNews CoverageDYNDyne Therapeutics3.5742 of 5 stars$15.29-3.7%$49.91+226.4%-15.1%$1.56BN/A-4.29100Analyst ForecastIMCRImmunocore2.3806 of 5 stars$30.03-1.2%$65.64+118.6%-60.0%$1.50B$296.31M-31.61497EVOEvotec2.2381 of 5 stars$4.18-4.1%$5.93+41.9%-49.0%$1.48B$777.05M0.004,200Short Interest ↑TVTXTravere Therapeutics2.8643 of 5 stars$18.59+2.8%$23.67+27.3%+99.0%$1.45B$203.45M-4.09460Analyst ForecastAnalyst RevisionNews CoverageVIRVir Biotechnology4.1821 of 5 stars$10.52-13.1%$34.83+231.1%+0.8%$1.45B$62.04M-2.68580Analyst RevisionGPCRStructure Therapeutics1.6 of 5 stars$25.16-0.4%$81.29+223.1%-38.4%$1.44BN/A-34.00136Short Interest ↑ Related Companies and Tools Related Companies Galapagos Competitors Arcutis Biotherapeutics Competitors Indivior Competitors Akero Therapeutics Competitors Dyne Therapeutics Competitors Immunocore Competitors Evotec Competitors Travere Therapeutics Competitors Vir Biotechnology Competitors Structure Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATXS) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXS Stock Alerts